About
At Akasi Pharma, we are dedicated to develping safe and efficacious non-opioid therapeutics to treat peripheral neuopathic pain. Inspired by the fish-hunting marine cone snails, we have developed the most potent and selective activators of the somatostatin receptor 4, an intruiging new pain target that was recently clinically validated.
Our inital target indication is diabetic peripheral neuropathic pain (DPNP), a detrimental persitent pain condition with a life time incidence in diabetics of 50 %. DPNP has proven notoriously difficult to treat, with fewer than half of patients finding sufficient relief from current treatments. The dedicated team at Akasi Pharma is working to provide the best-in-class solutions for these patients.
